Bioethics News

FDA Approves Sarepta’s Controversial Drug for Duchenne Muscular Dystrophy

The Food and Drug Administration on Monday approved a controversial drug to treat Duchenne muscular dystrophy, a rare disease that confines boys to wheelchairs and condemns them to an early death.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.